AB Corporate Bond ETF (NASDAQ:EYEG) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

AB Corporate Bond ETF (NASDAQ:EYEG) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $35.56 and traded as high as $35.63. AB Corporate Bond ETF shares last traded at $35.67, with a volume of 15 shares.

AB Corporate Bond ETF Trading Up 0.6%

The firm has a market capitalization of $28.54 million, a PE ratio of -21.23 and a beta of 0.23. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.01. The business’s fifty day moving average price is $35.56 and its 200 day moving average price is $35.85.

AB Corporate Bond ETF Increases Dividend

The company also recently declared a monthly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Wednesday, April 1st were issued a dividend of $0.1433 per share. This represents a c) dividend on an annualized basis and a dividend yield of 4.8%. This is a boost from AB Corporate Bond ETF’s previous monthly dividend of $0.14. The ex-dividend date was Wednesday, April 1st. AB Corporate Bond ETF’s payout ratio is presently -104.17%.

Institutional Investors Weigh In On AB Corporate Bond ETF

Hedge funds and other institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC grew its holdings in AB Corporate Bond ETF by 32.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock valued at $5,634,000 after purchasing an additional 38,685 shares during the period. Jane Street Group LLC grew its holdings in AB Corporate Bond ETF by 166.7% in the fourth quarter. Jane Street Group LLC now owns 15,741 shares of the specialty pharmaceutical company’s stock valued at $563,000 after purchasing an additional 9,839 shares during the period. Finally, Kestra Advisory Services LLC purchased a new stake in AB Corporate Bond ETF in the fourth quarter valued at approximately $34,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.